Literature DB >> 22266893

Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.

Joshua J Gagne1, Jeremy A Rassen, Alexander M Walker, Robert J Glynn, Sebastian Schneeweiss.   

Abstract

BACKGROUND: Active medical-product-safety surveillance systems are being developed to monitor many products and outcomes simultaneously in routinely collected longitudinal electronic healthcare data. These systems will rely on algorithms to generate alerts about potential safety concerns.
METHODS: We compared the performance of 5 classes of algorithms in simulated data using a sequential matched-cohort framework, and applied the results to 2 electronic healthcare databases to replicate monitoring of cerivastatin-induced rhabdomyolysis. We generated 600,000 simulated scenarios with varying expected event frequency in the unexposed, alerting threshold, and outcome risk in the exposed, and compared the alerting algorithms in each scenario type using an event-based performance metric.
RESULTS: We observed substantial variation in algorithm performance across the groups of scenarios. Relative performance varied by the event frequency and by user-defined preferences for sensitivity versus specificity. Type I error-based statistical testing procedures achieved higher event-based performance than other approaches in scenarios with few events, whereas statistical process control and disproportionality measures performed relatively better with frequent events. In the empirical data, we observed 6 cases of rhabdomyolysis among 4294 person-years of follow-up, with all events occurring among cerivastatin-treated patients. All selected algorithms generated alerts before the drug was withdrawn from the market.
CONCLUSIONS: For active medical-product-safety monitoring in a sequential matched cohort framework, no single algorithm performed best in all scenarios. Alerting algorithm selection should be tailored to particular features of a product-outcome pair, including the expected event frequencies and trade-offs between false-positive and false-negative alerting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266893      PMCID: PMC3285473          DOI: 10.1097/EDE.0b013e3182459d7d

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  22 in total

1.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.

Authors:  Eugène P van Puijenbroek; Andrew Bate; Hubert G M Leufkens; Marie Lindquist; Roland Orre; Antoine C G Egberts
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Jan-Feb       Impact factor: 2.890

Review 2.  Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.

Authors:  Bruce M Psaty; Curt D Furberg; Wayne A Ray; Noel S Weiss
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

3.  An application of propensity score matching using claims data.

Authors:  John D Seeger; Paige L Williams; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-07       Impact factor: 2.890

Review 4.  A review of uses of health care utilization databases for epidemiologic research on therapeutics.

Authors:  Sebastian Schneeweiss; Jerry Avorn
Journal:  J Clin Epidemiol       Date:  2005-04       Impact factor: 6.437

Review 5.  Indications for propensity scores and review of their use in pharmacoepidemiology.

Authors:  Robert J Glynn; Sebastian Schneeweiss; Til Stürmer
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-03       Impact factor: 4.080

6.  Real-time vaccine safety surveillance for the early detection of adverse events.

Authors:  Tracy A Lieu; Martin Kulldorff; Robert L Davis; Edwin M Lewis; Eric Weintraub; Katherine Yih; Ruihua Yin; Jeffrey S Brown; Richard Platt
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

7.  Early detection of adverse drug events within population-based health networks: application of sequential testing methods.

Authors:  Jeffrey S Brown; Martin Kulldorff; K Arnold Chan; Robert L Davis; David Graham; Parker T Pettus; Susan E Andrade; Marsha A Raebel; Lisa Herrinton; Douglas Roblin; Denise Boudreau; David Smith; Jerry H Gurwitz; Margaret J Gunter; Richard Platt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-12       Impact factor: 2.890

8.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Authors:  David J Graham; Judy A Staffa; Deborah Shatin; Susan E Andrade; Stephanie D Schech; Lois La Grenade; Jerry H Gurwitz; K Arnold Chan; Michael J Goodman; Richard Platt
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

9.  High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.

Authors:  Sebastian Schneeweiss; Jeremy A Rassen; Robert J Glynn; Jerry Avorn; Helen Mogun; M Alan Brookhart
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

10.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

View more
  12 in total

1.  Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.

Authors:  Rolina D van Gaalen; Michal Abrahamowicz; David L Buckeridge
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

2.  The Potential Return on Public Investment in Detecting Adverse Drug Effects.

Authors:  Krista F Huybrechts; Rishi J Desai; Moa Park; Joshua J Gagne; Mehdi Najafzadeh; Jerry Avorn
Journal:  Med Care       Date:  2017-06       Impact factor: 2.983

3.  Harnessing a health information exchange to identify surgical device adverse events for urogynecologic mesh.

Authors:  Jeanne Ballard; Marc Rosenman; Michael Weiner
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

4.  A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.

Authors:  Joshua J Gagne; Shirley V Wang; Jeremy A Rassen; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-04-30       Impact factor: 2.890

5.  A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.

Authors:  Yihua Xu; Xiaofeng Zhou; Brandon T Suehs; Abraham G Hartzema; Michael G Kahn; Yola Moride; Brian C Sauer; Qing Liu; Keran Moll; Margaret K Pasquale; Vinit P Nair; Andrew Bate
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

6.  Continuous Post-Market Sequential Safety Surveillance with Minimum Events to Signal.

Authors:  Martin Kulldorff; Ivair R Silva
Journal:  Revstat Stat J       Date:  2017-07       Impact factor: 0.985

7.  Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.

Authors:  Joshua J Gagne; Jeremy A Rassen; Niteesh K Choudhry; Rhonda L Bohn; Amanda R Patrick; Gayathri Sridhar; Gregory W Daniel; Jun Liu; Sebastian Schneeweiss
Journal:  Drug Saf       Date:  2014-03       Impact factor: 5.606

8.  The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist.

Authors:  Nicholas Moore
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

9.  Sequential cohort design applying propensity score matching to analyze the comparative effectiveness of atorvastatin and simvastatin in preventing cardiovascular events.

Authors:  Arja Helin-Salmivaara; Piia Lavikainen; Emma Aarnio; Risto Huupponen; Maarit Jaana Korhonen
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

10.  Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system.

Authors:  J J Gagne; R J Glynn; J A Rassen; A M Walker; G W Daniel; G Sridhar; S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2012-05-16       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.